Edwards Lifesciences Corporation (EW)

In the past six months, Edwards Lifesciences' stock price has risen by 9.33%. Revenue expectations for FY2025 have been revised upward by 1.22% over the past three months, during which the stock price increased by 10.53%. Analysts forecast the EW stock price to rise over the next 12 months, with an average 1-year price target of $82.91. Recent earnings reports include Q4 2023, Q2 2024, and Q4 2024 results, with varying sales growth and adjusted EPS. Edwards Lifesciences is scheduled to release its Q2 2025 earnings report on July 24, 2025. The stock has experienced some volatility, with a 1.55% volatility and a beta coefficient of 0.63. As of July 18, 2025, the stock was up 3.39% over the past 30 days but down 10.86% over the past 12 months.

Edwards Lifesciences' products are used to treat advanced cardiovascular diseases, implying a relatively consistent demand driven by patient needs rather than strong seasonal fluctuations. Hospital staffing constraints and holiday seasons can impact procedure volumes. Historically, buying Edwards Lifesciences Corp (EW) stock in March has shown the highest probability of a positive return, while September has the lowest probability. The company's earnings reports indicate varying growth rates across quarters for its different product groups, which could be influenced by factors like product launches, market adoption, and broader healthcare trends.

Edwards Lifesciences Corp. is a global medical technology company focused on patient-centered innovations for structural heart disease and critical care monitoring, operating in the Healthcare Equipment & Supplies industry. The company is known for its heart valve replacement and hemodynamic monitoring technologies. Its major product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart Solutions, and Critical Care. Edwards Lifesciences plans to spin-off its Critical Care product group around the end of 2024.

Edwards Lifesciences has a global presence with operations in the United States, Europe, Japan, Latin America, and Asia, with approximately 60% of sales from international markets. The company's global headquarters is in Irvine, California, USA, and it has major manufacturing facilities in the U.S., Dominican Republic, Costa Rica, Singapore, Puerto Rico, and Ireland. Edwards Lifesciences sells its products in approximately 100 countries.

Edwards Lifesciences maintains a strong brand reputation as a global leader in structural heart innovation, known for its commitment to improving patient lives through innovative technologies. Continued innovation and product launches, such as EVOQUE and the expansion of its RESILIA tissue portfolio, contribute positively to its reputation. Strong financial performance and R&D investment further enhance its brand. However, underperformance relative to the industry and market, unfavorable foreign exchange impacts, and hospital staffing constraints have had some negative impacts.

Edwards Lifesciences is primarily owned by institutional shareholders (84.90%), with 1.22% owned by Edwards Lifesciences insiders and 13.88% by retail investors. Major institutional owners include Vanguard Group Inc, Blackrock Inc, Wellington Management Group LLP, State Street Corp, and JPMorgan Chase & Co. The largest individual shareholder is Michael A. Mussallem, owning 0.76% of the company. Insiders have generally been net sellers of EW stock.